Cargando…

Effect of resveratrol on non-alcoholic fatty liver disease

The aim of the present study was to investigate the effect of a micronized formulation of trans-resveratrol in humans with non-alcoholic fatty liver disease (NAFLD). Trans-Resveratrol has been used in the form of micronized formulation, which is better absorbed, has strong antioxidants effects, is m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Theodotou, Marios, Fokianos, Konstantinos, Moniatis, Demetris, Kadlenic, Rudolf, Chrysikou, Asimina, Aristotelous, Andrea, Mouzouridou, Alexia, Diakides, John, Stavrou, Eliza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566048/ https://www.ncbi.nlm.nih.gov/pubmed/31316594 http://dx.doi.org/10.3892/etm.2019.7607

Ejemplares similares

The effect of resveratrol on hypertension: A clinical trial
por: Theodotou, Marios, et al.
Publicado: (2017)

Comparison of two-view versus single-view digital breast tomosynthesis and 2D-mammography in breast cancer surveillance imaging
por: Hadjipanteli, Andria, et al.
Publicado: (2021)

Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy
por: Wan, Shuqian, et al.
Publicado: (2018)

Alleviation Effects of Microbial Metabolites from Resveratrol on Non-Alcoholic Fatty Liver Disease
por: Guo, Jingling, et al.
Publicado: (2022)

Correction to ‘Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy’
por: Wan, S., et al.
Publicado: (2019)

Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease—A Meta-Analysis
por: Jakubczyk, Karolina, et al.
Publicado: (2020)

Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota
por: Du, Fan, et al.
Publicado: (2021)

Polydatin, A Glycoside of Resveratrol, Is Better Than Resveratrol in Alleviating Non-alcoholic Fatty Liver Disease in Mice Fed a High-Fructose Diet
por: Zhao, Guangshan, et al.
Publicado: (2022)

Resveratrol inhibits nonalcoholic fatty liver disease in rats
por: Bujanda, Luis, et al.
Publicado: (2008)

Resveratrol improves alcoholic fatty liver disease by downregulating HIF-1α expression and mitochondrial ROS production
por: Ma, Zhenhua, et al.
Publicado: (2017)

Effect of resveratrol on alcohol-induced mortality and liver lesions in mice
por: Bujanda, Luis, et al.
Publicado: (2006)

Cardiovascular disease in patients with non-alcoholic fatty liver disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials
por: Zhang, Chongyang, et al.
Publicado: (2016)

Resveratrol Ameliorates Experimental Alcoholic Liver Disease by Modulating Oxidative Stress
por: Peiyuan, He, et al.
Publicado: (2017)

Alcohol consumption in patients with nonalcoholic fatty liver disease: yes, or no?
por: Protopapas, Adonis A., et al.
Publicado: (2021)

Platelets in Non-alcoholic Fatty Liver Disease
por: Dalbeni, Andrea, et al.
Publicado: (2022)

The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis
por: Aristotelous, Panayiotis, et al.
Publicado: (2021)

Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease()
por: Khambu, Bilon, et al.
Publicado: (2018)

Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver
por: Foroughi, Mehdi, et al.
Publicado: (2016)

Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
por: Cainelli, Francesca, et al.
Publicado: (2020)

The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
por: Perakakis, Nikolaos, et al.
Publicado: (2020)

Molecular mechanism of alcoholic fatty liver
por: Rasineni, Karuna, et al.
Publicado: (2012)

Non-alcoholic fatty liver disease
por: Sattar, Naveed, et al.
Publicado: (2014)

Lipophagy and Alcohol-Induced Fatty Liver
por: Yang, Li, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Distinct Effects of Calorie Restriction and Resveratrol on Diet-Induced Obesity and Fatty Liver Formation
por: Tauriainen, Eveliina, et al.
Publicado: (2011)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
por: Valenzuela-Vallejo, Laura, et al.
Publicado: (2023)

Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease
por: Wu, Dongqing, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease and liver secretome
por: Khan, Muhammad Sohaib, et al.
Publicado: (2022)

Role of fatty liver index in risk-stratifying comorbid disease outcomes in non-alcoholic fatty liver disease
por: Ho, Brian, et al.
Publicado: (2023)

Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different
por: Malnick, Stephen D. H., et al.
Publicado: (2022)

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
por: Yu, Cheng-Wei, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers
por: Anavi, Sarit, et al.
Publicado: (2017)

Resveratrol and Quercetin Administration Improves Antioxidant DEFENSES and reduces Fatty Liver in Metabolic Syndrome Rats
por: Rubio-Ruiz, Maria Esther, et al.
Publicado: (2019)

Development of resveratrol with thiolated alginate as a supplement to prevent nonalcoholic fatty liver disease (NAFLD)
por: Ke, Yong-Chen, et al.
Publicado: (2022)

Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep’s Clothing?
por: Mitsala, Athanasia, et al.
Publicado: (2022)

Targeting Sirt1 in a rat model of high-fat diet-induced non-alcoholic fatty liver disease: Comparison of Gegen Qinlian decoction and resveratrol
por: Guo, Yi, et al.
Publicado: (2017)

Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Treatment of non-alcoholic fatty liver disease
por: Tolman, Keith G, et al.
Publicado: (2007)

Pathogenesis of non-alcoholic fatty liver disease
por: Dowman, J. K., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_md631e07jpnncju8lih67sc250